APA (7th ed.) Citation

Embaby, A., Kutzera, J., Geenen, J. J., Pluim, D., Hofland, I., Sanders, J., . . . Opdam, F. L. (2023). WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study. Gynecologic oncology, 174, 239-246. https://doi.org/10.1016/j.ygyno.2023.05.063

Chicago Style (17th ed.) Citation

Embaby, Alaa, et al. "WEE1 Inhibitor Adavosertib in Combination with Carboplatin in Advanced TP53 Mutated Ovarian Cancer: A Biomarker-enriched Phase II Study." Gynecologic Oncology 174 (2023): 239-246. https://doi.org/10.1016/j.ygyno.2023.05.063.

MLA (9th ed.) Citation

Embaby, Alaa, et al. "WEE1 Inhibitor Adavosertib in Combination with Carboplatin in Advanced TP53 Mutated Ovarian Cancer: A Biomarker-enriched Phase II Study." Gynecologic Oncology, vol. 174, 2023, pp. 239-246, https://doi.org/10.1016/j.ygyno.2023.05.063.